Abstract

The aim of this study was the development of optimal sustained-release moxifloxacin (MOX)-loaded liposomes as intraocular therapeutics of endophthalmitis. Two methods were compared for the preparation of MOX liposomes; the dehydration–rehydration (DRV) method and the active loading method (AL). Numerous lipid-membrane compositions were studied to determine the potential effect on MOX loading and retention in liposomes. MOX and phospholipid contents were measured by HPLC and a colorimetric assay for phospholipids, respectively. Vesicle size distribution and surface charge were measured by DLS, and morphology was evaluated by cryo-TEM. The AL method conferred liposomes with higher MOX encapsulation compared to the DRV method for all the lipid compositions used. Cryo-TEM showed that both liposome types had round vesicular structure and size around 100–150 nm, while a granular texture was evident in the entrapped aqueous compartments of most AL liposomes, but substantially less in DRV liposomes; X-ray diffraction analysis demonstrated slight crystallinity in AL liposomes, especially the ones with highest MOX encapsulation. AL liposomes retained MOX for significantly longer time periods compared to DRVs. Lipid composition did not affect MOX release from DRV liposomes but significantly altered drug loading/release in AL liposomes. Interestingly, AL liposomes demonstrated substantially higher antimicrobial potential towards S. epidermidis growth and biofilm susceptibility compared to corresponding DRV liposomes, indicating the importance of MOX retention in liposomes on their activity. In conclusion, the liposome preparation method/type determines the rate of MOX release from liposomes and modulates their antimicrobial potential, a finding that deserves further in vitro and in vivo exploitation.

Highlights

  • Licensee MDPI, Basel, Switzerland.Moxifloxacin hydrochloride (MOX) is a fourth-generation fluoroquinolone with a dual antimicrobial mechanism of action [1]

  • Where physicochemical properties of MOX liposomes are presented, the AL method produced liposomes with 50–81% higher MOX-loading efficiencies as compared to the corresponding dehydration–rehydration vesicle (DRV) liposomes in all cases. It should be noted at this point that PC liposomes prepared by conventional thin-film hydration method had a MOX encapsulation efficiency equal to 0.35%, more than 30 times lower than the corresponding DRV liposomes, justifying the selection of the DRV method as a passive drug loading method that could be compared with the active loading method

  • The DRV and AL methodologies, are used for liposome preparation, and the two liposome types are compared for their physicochemical properties, morphology, stability, MOX encapsulation efficiency, and MOX

Read more

Summary

Introduction

Licensee MDPI, Basel, Switzerland.Moxifloxacin hydrochloride (MOX) is a fourth-generation fluoroquinolone with a dual antimicrobial mechanism of action [1]. While earlier fluoroquinolones had a limited spectrum of antimicrobial activity (mainly restricted to Gram-negative pathogens), numerous chemical modifications of the quinolone molecule resulted in increased activity, changes in pharmacokinetic characteristics, and decreased toxicity. In this context, MOX demonstrates enhanced activity against Gram-positive organisms and anaerobes and reduces the published maps and institutional affil-. As a result of enhanced cell interaction, increased therapeutic properties of MOX as compared to other fluoroquinolones make it an ideal drug for the treatment of ocular infections, such as endophthalmitis; MOX has been proven as a safe prophylactic treatment following cataract surgery [6,7,8,9,10]

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call